Immunome, Inc. (IMNM) is in Healthcare, Biotechnology, based in United States, listed on NasdaqCM. Market cap 2.28B USD. 52-week range 13.49 to 30.06 USD. Data as of 2026-10-09.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It ...